JP2024546605A5 - - Google Patents
Info
- Publication number
- JP2024546605A5 JP2024546605A5 JP2024531205A JP2024531205A JP2024546605A5 JP 2024546605 A5 JP2024546605 A5 JP 2024546605A5 JP 2024531205 A JP2024531205 A JP 2024531205A JP 2024531205 A JP2024531205 A JP 2024531205A JP 2024546605 A5 JP2024546605 A5 JP 2024546605A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical product
- product according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163265441P | 2021-12-15 | 2021-12-15 | |
| US63/265,441 | 2021-12-15 | ||
| PCT/US2022/081592 WO2023114871A1 (en) | 2021-12-15 | 2022-12-14 | Use of combination therapy for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546605A JP2024546605A (ja) | 2024-12-26 |
| JP2024546605A5 true JP2024546605A5 (https=) | 2026-01-15 |
Family
ID=86773654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531205A Pending JP2024546605A (ja) | 2021-12-15 | 2022-12-14 | がんを治療するための併用療法の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240325397A1 (https=) |
| EP (1) | EP4447973A4 (https=) |
| JP (1) | JP2024546605A (https=) |
| KR (1) | KR20240119096A (https=) |
| CN (1) | CN119136807A (https=) |
| AU (1) | AU2022409798A1 (https=) |
| CA (1) | CA3242265A1 (https=) |
| MX (1) | MX2024007260A (https=) |
| TW (1) | TW202333675A (https=) |
| WO (1) | WO2023114871A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| WO2025123287A1 (en) * | 2023-12-14 | 2025-06-19 | Remegen Co., Ltd. | Methods of treating breast cancer using anti-her2 antibody-drug conjugates and other therapeutic agents |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
| WO2025231223A1 (en) * | 2024-05-02 | 2025-11-06 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
-
2022
- 2022-12-14 MX MX2024007260A patent/MX2024007260A/es unknown
- 2022-12-14 EP EP22908677.2A patent/EP4447973A4/en active Pending
- 2022-12-14 CN CN202280082158.0A patent/CN119136807A/zh active Pending
- 2022-12-14 CA CA3242265A patent/CA3242265A1/en active Pending
- 2022-12-14 AU AU2022409798A patent/AU2022409798A1/en active Pending
- 2022-12-14 KR KR1020247022101A patent/KR20240119096A/ko active Pending
- 2022-12-14 JP JP2024531205A patent/JP2024546605A/ja active Pending
- 2022-12-14 WO PCT/US2022/081592 patent/WO2023114871A1/en not_active Ceased
- 2022-12-15 TW TW111148297A patent/TW202333675A/zh unknown
-
2024
- 2024-06-14 US US18/743,564 patent/US20240325397A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024546605A5 (https=) | ||
| JP2025041725A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| JP2022511351A5 (https=) | ||
| RU2007101378A (ru) | Терапия злокачественной опухоли, резистентной к препаратам на основе платины | |
| JP2025061126A (ja) | Ｒｏｒ１抗体イムノコンジュゲートによる癌の治療 | |
| JP2020515578A5 (https=) | ||
| JP2023076588A (ja) | 乳癌のための、ネラチニブを活用する治療計画 | |
| JP2017031160A5 (https=) | ||
| JP2008503476A5 (https=) | ||
| JP2012522512A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| JP2023502929A5 (https=) | ||
| JP2022523740A5 (https=) | ||
| JP2023545096A5 (https=) | ||
| JP2022537269A5 (https=) | ||
| JP2019517485A5 (https=) | ||
| JP2025509266A5 (https=) | ||
| JP2021523100A5 (https=) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2021515017A5 (https=) | ||
| JP2021503915A5 (https=) | ||
| JP2022541591A5 (https=) | ||
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2022523045A5 (https=) |